Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Myeloid Phagocyte Activation by Commensal-Activated Complement C5aR1 Signaling: Implications for Tumor-Directed Lymphocyte Response

Award Number: R21CA293616
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 05/01/2026
PERIOD OF PERFORMANCE END DATE: 04/30/2028

Group Awards By:

View Award Description

Myeloid Phagocyte Activation by Commensal-Activated Complement C5aR1 Signaling: Implications for Tumor-Directed Lymphocyte Response - PROJECT SUMMARY The complement peptide C5a, traditionally considered a liver-derived serum protein, is now recognized to be locally produced and activated within the tumor microenvironment. Our data and others' show that epi- thelial and myeloid cells harbor intracellular C5 stores that can be induced and activated by microbial signals – particularly relevant at the gastrointestinal (GI) mucosa. Fusobacterium nucleatum and Candida albicans, two microbes enriched in colorectal cancer (CRC), are known to promote tumor progression by enhancing myeloid infiltration, dampening anti-tumor T-cell responses, and fueling inflammation. However, how these microbes interface with C5aR1 signaling to shape the CRC tumor microenvironment remains unclear. Our preliminary data show that C. albicans and bacterial LPS boost intracellular C5/C5a production in human monocytes and CRC cells. Spatial and single-cell transcriptomics of human CRC tumors reveal increased complement activation, C5aR1 expression, and macrophage infiltration – suggesting a central role for C5aR1 in modulating tumor immunity. Moreover, the ability of C. albicans and F. nucleatum to co-aggregate suggests potential synergy in driving C5aR1-mediated effects. We hypothesize that C5aR1 promotes tumor progression by orchestrating a myeloid-driven, inflammatory and immunosuppressive tumor microenviron- ment, potentiated by complement-inductive signals from CRC-enriched microbes such as Candida albicans and Fusobacterium nucleatum. To test this hypothesis, we will (Aim 1) assess the independent and syner- gistic effects of C. albicans and F. nucleatum on C5aR1-dependent tumor progression, and (Aim 2) define the roles of macrophage- and epithelial-intrinsic C5aR1 signaling. By uncovering how tumor-associated mi- crobes amplify C5aR1 signaling, this work will inform novel strategies for microbe-informed, complement- targeted CRC therapies.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $467,261 )
2026	2026	HMH HOSPITALS CORPORATION	343 THORNALL ST	EDISON	NJ	08837	MIDDLESEX	USA	Cancer Cause and Prevention Research	001	1	5/7/2026	NEW	$0
2026	2026	HMH HOSPITALS CORPORATION	343 THORNALL ST	EDISON	NJ	08837	MIDDLESEX	USA	Cancer Cause and Prevention Research	000	1	4/29/2026	NEW	$467,261
														Subtotal = $467,261

Grand Total All Awards = $467,261

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Myeloid Phagocyte Activation by Commensal-Activated Complement C5aR1 Signaling: Implications for Tumor-Directed Lymphocyte Response

Award Number: R21CA293616

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 05/01/2026

PERIOD OF PERFORMANCE END DATE: 04/30/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer